Larry Biegelsen
Stock Analyst at Wells Fargo
(4.21)
# 471
Out of 4,712 analysts
290
Total ratings
57.73%
Success rate
11.14%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Maintains: Overweight | $405 → $427 | $370.16 | +15.36% | 14 | Dec 11, 2024 | |
| GKOS Glaukos | Maintains: Overweight | $145 → $153 | $151.22 | +1.18% | 12 | Dec 11, 2024 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $10 → $8 | $6.16 | +29.87% | 6 | Dec 11, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $549 → $630 | $537.02 | +17.31% | 18 | Dec 11, 2024 | |
| DXCM DexCom | Maintains: Overweight | $90 → $94 | $80.24 | +17.15% | 9 | Dec 11, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $98 → $100 | $91.07 | +9.81% | 12 | Dec 11, 2024 | |
| RXST RxSight | Downgrades: Equal-Weight | $56 → $42 | $34.47 | +21.85% | 8 | Dec 11, 2024 | |
| MMSI Merit Medical Systems | Upgrades: Overweight | $103 → $120 | $98.08 | +22.35% | 7 | Dec 11, 2024 | |
| PEN Penumbra | Upgrades: Overweight | $190 → $275 | $240.36 | +14.41% | 14 | Dec 11, 2024 | |
| COO The Cooper Companies | Maintains: Overweight | $115 → $118 | $92.81 | +27.14% | 16 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $98 | $81.54 | +20.19% | 17 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $187 → $198 | $186.29 | +6.29% | 10 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $96 | $79.36 | +20.97% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $26 | $17.86 | +45.58% | 3 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $117 | $107.30 | +9.04% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $163 → $166 | $145.85 | +13.82% | 12 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $80 | $75.38 | +6.13% | 15 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $105 | $86.08 | +21.98% | 8 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $44 → $40 | $29.08 | +37.55% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $37.00 | +48.65% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $65 | $53.65 | +21.16% | 5 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $40 | $30.97 | +29.16% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $14 | $3.97 | +252.64% | 11 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.1 → $1.6 | $0.86 | +86.05% | 3 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $22.13 | +121.42% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $241 → $236 | $176.88 | +33.42% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $114.66 | +18.61% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $83.47 | -16.14% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $226.95 | +18.97% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $91.30 | - | 2 | Nov 2, 2017 |
Stryker
Dec 11, 2024
Maintains: Overweight
Price Target: $405 → $427
Current: $370.16
Upside: +15.36%
Glaukos
Dec 11, 2024
Maintains: Overweight
Price Target: $145 → $153
Current: $151.22
Upside: +1.18%
Pulmonx
Dec 11, 2024
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $6.16
Upside: +29.87%
Intuitive Surgical
Dec 11, 2024
Maintains: Overweight
Price Target: $549 → $630
Current: $537.02
Upside: +17.31%
DexCom
Dec 11, 2024
Maintains: Overweight
Price Target: $90 → $94
Current: $80.24
Upside: +17.15%
Boston Scientific
Dec 11, 2024
Maintains: Overweight
Price Target: $98 → $100
Current: $91.07
Upside: +9.81%
RxSight
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $56 → $42
Current: $34.47
Upside: +21.85%
Merit Medical Systems
Dec 11, 2024
Upgrades: Overweight
Price Target: $103 → $120
Current: $98.08
Upside: +22.35%
Penumbra
Dec 11, 2024
Upgrades: Overweight
Price Target: $190 → $275
Current: $240.36
Upside: +14.41%
The Cooper Companies
Dec 6, 2024
Maintains: Overweight
Price Target: $115 → $118
Current: $92.81
Upside: +27.14%
Nov 20, 2024
Maintains: Overweight
Price Target: $106 → $98
Current: $81.54
Upside: +20.19%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $187 → $198
Current: $186.29
Upside: +6.29%
Oct 31, 2024
Maintains: Overweight
Price Target: $95 → $96
Current: $79.36
Upside: +20.97%
Oct 31, 2024
Maintains: Overweight
Price Target: $23 → $26
Current: $17.86
Upside: +45.58%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $110 → $117
Current: $107.30
Upside: +9.04%
Oct 16, 2024
Maintains: Equal-Weight
Price Target: $163 → $166
Current: $145.85
Upside: +13.82%
Sep 9, 2024
Maintains: Overweight
Price Target: $90 → $80
Current: $75.38
Upside: +6.13%
Aug 22, 2024
Maintains: Overweight
Price Target: $94 → $105
Current: $86.08
Upside: +21.98%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $44 → $40
Current: $29.08
Upside: +37.55%
Aug 2, 2024
Maintains: Overweight
Price Target: $50 → $55
Current: $37.00
Upside: +48.65%
Jul 31, 2024
Maintains: Overweight
Price Target: $84 → $65
Current: $53.65
Upside: +21.16%
Jul 26, 2024
Maintains: Overweight
Price Target: $42 → $40
Current: $30.97
Upside: +29.16%
Apr 8, 2024
Maintains: Equal-Weight
Price Target: $17 → $14
Current: $3.97
Upside: +252.64%
Mar 22, 2024
Maintains: Equal-Weight
Price Target: $2.1 → $1.6
Current: $0.86
Upside: +86.05%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $22.13
Upside: +121.42%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $241 → $236
Current: $176.88
Upside: +33.42%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $114.66
Upside: +18.61%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $83.47
Upside: -16.14%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $226.95
Upside: +18.97%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $91.30
Upside: -